
|Videos|June 11, 2015
Two Doses of Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma
Author(s)Catherine M. Diefenbach, MD
Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
CRB-701 Shows Antitumor Activity in HNSCC
2
How Turning to Psychedelics Can Help Patients With Cancer Heal
3
ASCO 2026 Lung Cancer Abstracts: Clinical Practice Implications
4
Researchers Track the Memory of Cancer in Lynch Syndrome
5









































